Advertisement

Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha

      Abstract

      To clarify long-term effects of intrathecal administration of interferon (IFN)-α in subacute sclerosing panencephalitis (SSPE), we followed up a patient with SSPE for 18 years, who had been treated successfully using intrathecal IFN-α with response-based dose adjustments. IFN-α therapy dramatically induced remission of disease and greatly improved quality of life for 7–8 years, but this was followed by severely deterioration with decorticate posturing and akinetic mutism. Thus, IFN-α-induced remission appears most likely to be temporary, even when an SSPE patient shows an excellent initial response. To improve long-term outcome for SSPE patients, more effective therapy is needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Inoue T.
        • Kira R.
        • Nakao F.
        • Ihara K.
        • Bassuny W.M.
        • Kusuhara K.
        • et al.
        Contribution of the interleukin 4 gene to susceptibility to subacute sclerosing panencephalitis.
        Arch Neurol. 2002; 59: 822-827
        • Risk W.S.
        • Haddad F.S.
        The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East.
        Arch Neurol. 1979; 36: 610-614
        • Miyazaki M.
        • Hashimoto T.
        • Fujino K.
        • Goda T.
        • Tayama M.
        • Kuroda Y.
        Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha.
        Ann Neurol. 1991; 29: 97-99
        • Freeman J.M.
        The clinical spectrum and early diagnosis of Dawson's encephalitis; with preliminary notes on treatment.
        J Pediatr. 1969; 75: 590-603
        • Yalaz K.
        • Anlar B.
        • Oktem F.
        • Aysun S.
        • Ustacelebi S.
        • Gurcay O.
        • et al.
        Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.
        Neurology. 1992; 42: 488-491
        • Anlar B.
        • Yalaz K.
        • Oktem F.
        • Kose G.
        Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular α -interferon.
        Neurology. 1997; 48: 526-528
        • Lebon P.
        • Boutin B.
        • Dulac O.
        • Ponsot G.
        • Arthuis M.
        Interferon in acute and subacute encephalitis.
        Br Med J. 1988; 296: 9-11
        • Gadoth N.
        • Kott E.
        • Levin S.
        • Hahn T.
        The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine.
        Brain Dev. 1989; 11: 308-312
        • Crespi M.
        • Chin M.N.
        • Schoub B.D.
        • Lyons S.F.
        Effect of interferon on Vero cells persistently infected with SSPE virus and lytically infected with measles virus.
        Arch Virol. 1986; 90: 87-96
        • Barkovich A.J.
        Pediatric Neuroimaging.
        3rd ed. Lippincott/ Williams & Wilkins, Philadelphia, PA/Baltimore, MD2000 (p. 749–750)